Could a simple blood or urine test replace prostate biopsies?
NCT ID NCT06144619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether non-invasive tests—like blood, urine, and genetic analysis—can help track prostate cancer progression without repeated biopsies. Researchers will follow 500 men with low, intermediate, or high-risk prostate cancer as they receive standard care. The goal is to find biomarkers that signal when the disease is getting worse, potentially reducing the need for invasive procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to monitor prostate cancer without repeated invasive biopsies, improving patient comfort and care decisions.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. It is currently suspended, and results may not change practice for years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?